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Association of coronary atherosclerosis diffusion, Framimgham score
(FRS) and the metabolic syndrome (MS) and its component: anangio-
graphy study
Monia Elasmi (1), Wiem Zidi (2), Yosra Zayani (1), Amira Zaroui [Ora-
teur] (1), Rachid Mechmeche (1), Sami Mourali (1), Neziha Kaabachi (1)
(1) Hôpital la Rabta, Explorations Fonctionnelles, Tunis, Tunisie – (2)
Hôpital La Rabta, Biochimie,Tunis, Tunisie
Study to evaluate the relationship between conventional assessment of
the global cardio-vascular risk by means of FRS and the MS and its dif-
ferent component with the coronary atherosclerosis severity.About 425
consecutives patients undergoing angiographic coronary exploration. The
severity of the atherosclerosis diffusion was assessed using a score
assessing the number of vessel-segment with a atherosclerotic plaque
(20% luminal vessel), patients were classed Into 5 groups . We found a
linear correlation between the coronary atherosclerosis diffusion score and
the MS and its component (p=0.04 for all factor) and with the mean of the
FRS. MS and FSR were assessed respectively for the group score0 at:
47.1%,10.9±8.1,group score1 at 44.8%,15±10 , group score 2 at 68.1%,
17±10 , score3 at 73.3%, 18±10 and score 4 at 62%, 28±15 , the difference
was statistically significant, p=0.002 for the MS , and p=0.003 for the FSR
Conclusion:Our study shows that increased FRS are associated with the
severity of the coronary atherosclerosis diffusion likely for the metabolic
syndrome and all its components.
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Comparison of rosuvastatin and atorvastatin on clopidogrel response
and lipidic and inflammatory parameters after coronary stenting for
acute coronary syndrome 
Raphaël Poyet [Orateur] (1), Thomas Cuisset (2), F X Brocq (1), Jacques Quilici
(2), Corinne Frère (3), Pierre Jean Moro (2), P E Morange (3), J L Bonnet (2)
(1) HIA Ste Anne, Cardiologie, Toulon, France – (2) AP-HM, CHU La
Timone, Cardiologie Interventionnelle, Marseille, France – (3) AP-HP,
CHU La Timone, Laboratoire d’Hématologie, Marseille, France
Objective: To compare the effect of high doses of rosuvastatin and atorv-
astatin on lipidic, inflammatory parameters and platelet response to clopido-
grel after coronary stenting for Non ST Elevation Acute Coronary Syndrome
(NSTE ACS).
Background: Use of atorvastatin has been reported to decrease signif-
icantly the clopidogrel antiplatelet effect because of cytochrome P450
interaction. Rosuvastatin, a recent developed statin is metabolized via a
different pathway. We investigated whether the coadministration of high
doses of atorvastatin or rosuvastatin for one month in patients with acute
coronary syndromes (ACS) could affect the antiplatelet potency of clopi-
dogrel.
Methods and Results: 138 patients undergoing coronary stenting for
NSTE ACS were prospectively included and randomized to rosuvastatin
20 mg (n=69) or atorvastatin 80 mg (n=69). They received at discharge 75 mg
aspirin and 150 mg clopidogrel. Platelet reactivity indexes VASP and ADP-
induced aggregation were used to assess clopidogrel response. After one
month, clopidogrel response was similar among patients receiving rosuvastatin
and atorvastatin: PRI VASP 44.6.±2.5% vs 46±2.3% respectively, p=0.66 and
ADP-Ag 53.3±1.7% vs 50±2.1% respectively , p=0.23..Inflammatory and
lipid parameters were similar between the two groups and the number of
patients reaching the target LDL cholesterol of less than 2.59 mmol/L was
similar in both groups: 74 % (n=51) with rosuvastatin and 71% (n=49) with
atorvastatin. P=0.85.
Conclusion: our present study suggests that in high risk patients, high dose
of atorvastatin has no negative effect on high maintenance dose of clopidogrel,
while providing same benefit on cholesterol lowering.
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Immediate and long term outcomes of the percutaneous coronary
intervention of the ostia of the major epicardial coronary arteries
Leila Abid [Orateur] (1), Majdi Abdennadher (1), Zied Frikha (1), S Mal-
lek (1), Mourad Hentati (1), Samir Kammoun (2)
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Background: The percutaneous treatment of coronary ostial disease repre-
sent a challenge for the interventional cardiologist and is associated with
higher procedural and long term complication rates. 
Aim of the study: To evaluate the immediate and long term outcomes of
the percutaneous coronary intervention of the major coronary artery ostial
lesion defined as a lesion arising within 3 mm of the vessel origin (LAD, CX,
and RCA)
Methods: A retrospective study on 80 patients, who underwent PCI for
ostial lesions of the left anterior descending, left circumflex, and right coro-
nary arteries over a period from 2001 to 2009 in the cardiology department of
the University Hedi Chaker Hospital of Sfax 
Results: The mean follow up of our patients was 31.17 months (±27,
5 months) .The mean age of our patients was 57.9 years; male predominance
was noted with sex ratio 2 /1. The Myocardial infarction (STEMI) was the
most common reason for admission (37 patients). The remaining patients have
either none elevated ST- Acute Coronary Syndromes (21 patients) nor stable
effort angina (22 patients).
The target lesion was the left anterior descending in 72.5%, the right cor-
onary artery in 21.3% and the circumflex artery in 6.3%.
The mean degree of stenosis was 82.6% (± 14.11) with a mean length of
16.30 mm (± 6, 6 mm). The PCI technic was mainly direct stenting in 54.4%,
a predilatation before stenting in 30.4% and a post dilatation was necessary in
3.8%. PTCA with balloon only has been practiced in 11.4% of cases. A
kissing balloon (LAD_CX) was performed in 18 patients (22.8%).
We used a bare metal stent in 93.1% of cases and drug eluting stent for
6.9% of our population study. 5 PCI were complicated: 2 cases of dissection,
2 effect snow plows (LAD – CX) and one coronary perforation with a proce-
dural complication rate of 6.3%.
42 patients (54.5%) were readmitted after PCI. Target Lesion revascular-
ization (TLR) was 18, 5% and the rate of composite MACE (Death, non fatal
MI, TLR) was 30 %
Conclusion: PCI of ostial narrowings of the major epicardial coronary
arteries was relatively safe. However it was associated with a high incidence
of adverse long term outcomes.
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Calcification in HIV-infected patients, assessed by coronary artery
calcium score (CACS): the VIHCAC study
Romain Chopard [Orateur] 
4, rue Roger Martin du Gard, 25000 Besançon
Background: Human immunodeficiency virus (HIV) – infected patients
may be at higher cardiovascular risk than the non-HIV population. The
VIHCAC study aimed to evaluate the Coronary Artery Calcium Score
(CACS) in comparison with the Framingham Risk Score (FRS) as a predictor
of cardiovascular risk.
Methods: Single-center, prospective cross-sectional study of patients with
HIV infection for more than 5 years and no history of coronary disease. Car-
diovascular risk was estimated by the Framingham Risk Score (FRS), CACS
was calculated using the Agatston method, based on coronary multidetector
computed tomography results. A CACS >10 was defined as abnormal. Inter-
leukin (IL)-6, ultra-sensitive C-reactive protein (us-CRP), glomerular filtration
rate (GFR), and fasting lipids were measured at enrolment. 
Results: 187 patients (mean age 48.7 years, mean HIV disease duration
12.6 years and mean anti-retrovirus exposure 11.1 years) were explored. FRS
was <10% in 113; 10-20% in 66; and >20% in 8. CACS was abnormal in 45
patients (10-100 in 26; 101-300 in 14; and >300 in 5). CACS and FRS corre-
lated poorly (r=0.15, p=0.04). Patients with abnormal CACS were older (53.1
vs. 47.4 years, p=0.0001), had lower GFR (85.7 vs. 98.0 ml/min, p=0.02), and
